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Abstract
Background: Single-stranded oligonucleotides (ssODN) are used routinely to direct specific base
alterations within mammalian genomes that result in the restoration of a functional gene. Despite
success with the technique, recent studies have revealed that following repair events, correction
frequencies decrease as a function of time, possibly due to a sustained activation of damage
response signals in corrected cells that lead to a selective stalling. In this study, we use thymidine
to slow down the replication rate to enhance repair frequency and to maintain substantial levels of
correction over time.
Results: First, we utilized thymidine to arrest cells in G1 and released the cells into S phase, at
which point specific ssODNs direct the highest level of correction. Next, we devised a protocol in
which cells are maintained in thymidine following the repair reaction, in which the replication is
slowed in both corrected and non-corrected cells and the initial correction frequency is retained.
We also present evidence that cells enter a senescence state upon prolonged treatment with
thymidine but this passage can be avoided by removing thymidine at 48 hours.
Conclusion: Taken together, we believe that thymidine may be used in a therapeutic fashion to
enable the maintenance of high levels of treated cells bearing repaired genes.
Background
A major goal of molecular medicine is to replace or repair
a dysfunctional gene in the context of its natural position
in the chromosome. A number of avenues of investigation
are being taken including those that utilize short oligonu-
cleotides to direct the single base changes. Triplex-helix
forming oligonucleotides conjugated to reactive chemical
groups and those constructed as bifunctional oligonucle-
otides continue to show promise in model systems [1-4].
Most of the effort however, centers on the use of modified
or unmodified single-stranded DNA oligonucleotides
(ssODNs) ranging in length from 25 to 75 bases. The orig-
inal concept for using ssODNs came from studies in yeast
in the 1980s that were pioneered by Sherman and col-
leagues [see [5]] and adapted to episomal targets in mam-
malian cells by Campbell et al. 1989. Gamper et al. [6,7]
and Liu et al. [8] then re-established single-stranded vec-
tors as potential agents for the alteration of chromosomal
sequences in eukaryotes.
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The mechanism by which oligonucleotides-directed gene
repair takes place is still being elucidated. One lab has
proposed that transcription-coupled repair alone can
account for base exchange or correction [9]. But, the
majority of workers believe that DNA replication and
DNA repair activities comprise the major pathway of gene
repair. This concept was originally proposed by Brachman
and Kmiec [10], subsequently extended by Parekh-
Olmedo et al. [11], and now has been supported by data
generated by numerous laboratories [12-17]. This model
suggests that actively replicating genomes are more ame-
nable to the hybridization of the ssODNs at the target site
because the chromatin is in a more open configuration
and the target sequence more accessible. The use of agents
such as hydroxyurea [18], ddC [19], or thymidine
[14,20,21] that retard the process of DNA replication ena-
ble higher levels of gene repair activity by expanding the
window of time within which the ssODN can locate its
target site.
The role of replication in the gene repair reaction, how-
ever, has recently been met with a paradoxical series of
events. The initialization of the gene repair reaction
results in a plethora of problems for the cell and its metab-
olism because an ATM-dependent DNA damage response
pathway is activated by the transfer of the ssODN [22],
confirming earlier observations by Liu [see [23]]. Acti-
vated ATM signals the induction of the checkpoint regula-
tor proteins Chk1 and Chk2, which in turn direct cell cycle
arrest predominantly in corrected cells. This result pro-
vided an explanation for the important observations of
Olsen et al. [12,13] that the percentage of corrected cells
in a population of treated cells decreases as a function of
time, presumably because the uncorrected population
continues to proliferate while the corrected cells are
arrested. If this phenomenon is applicable to primary
cells, then the use of gene repair for treating inherited dis-
eases will suffer a severe setback. The goal of this work was
to devise an experimental protocol to avert the dilution of
corrected cells in a population of treated cells.
As mentioned, the addition of thymidine to cells being
targeted for gene repair enhances the frequency with
which single base exchange takes place [14,18,21] by syn-
chronizing cells at the G1/S border (referred to as a thymi-
dine block) [24] followed by their release into S phase en
masse, which provides an increased number of accessible
targets for repair. In addition to the increase level of gene
repair observed after a thymidine treatment, we show that
the agent is able to stabilize the correction frequency over
several days, perhaps by inhibiting the replication of the
entire cell population and preventing a dilution effect on
the corrected cells. We also reveal a novel observation that
long-term exposure to thymidine results in the reversion
of DLD-1 cells into cellular senescence and that this can
be avoided by the removal of the drug prior to this point.
Based on this work and earlier observations, thymidine is
an attractive reagent for downstream clinical applications
due to its ability to elevate and maintain substantial levels
of gene repair without inducing severe toxicity in vitro.
Results
A mutant eGFP gene, containing a stop codon in the
region encoding the chromophore domain of the protein,
was integrated in DLD-1 cells and a clonal isolate consist-
ing of 2–3 copies of the mutated gene was isolated and
used as the target for oligonucleotide-directed gene repair
[10,18-22,25,26]. A single-strand oligonucleotide
(ssODN) consisting of 47 bases with three phospho-
rothioate linkages on each end, designed to hybridize to
the nontranscribed strand of the eGFP gene, was used to
reverse the mutation (TAG  → TAC),. As previously
reported, correction resulting in the restoration of green
fluorescence expression can be assessed by flow cytometry
analyses at various times following ssODN introduction
[18].
A variety of reagents have been tested with the aim of ele-
vating the frequency of gene repair in mammalian cells.
Among these are drugs that induce double-stranded DNA
breaks (ds breaks) and chemicals that form reversible
adducts within the helix [27]. In most cases, DNA damage
results in a slowing of the cell cycle and an expanded S
phase and so, reagents that simply reduce the rate of DNA
replication without causing double strand breaks have
also been found to improve the efficiency of gene repair
[10,19]. These agents are able to increase correction effi-
ciency by expanding the window of time within which the
ssODN gains access to the target site [10,19]. Thus, our
testable prediction is that a reagent such as thymidine,
which increases the cellular levels of dTTP via a depletion
of dCTP, resulting in a reduction in the rate of DNA repli-
cation [24], will increase gene repair activity.
Pre-incubation with thymidine elevates gene repair by 
increasing the number of cellular targets amenable for 
correction
Thymidine was added at various concentrations to the
DLD-1 mutant eGFP cell cultures 24 hours prior to the
introduction of the ssODN (EGFP3S/47NT) and correc-
tion levels were determined 48 hours after electroporation
by flow cytometry (Figure 1). The results show a maximal
response at concentrations of 1 and 8 mM thymidine,
with a significant increase of about 3 fold from the non-
treated sample. The decrease in correction efficiency as
seen at higher concentrations of thymidine (10 and 12
mM) is most likely due to the enhanced thymidine cyto-
toxicity reported previously in DLD-1 cells due to their
mutation in Msh6 [28]. Although these results differ from
the observation of Wu et al. [14], who stated that the incu-BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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bation of thymidine prior to the introduction of the oligo-
nucleotide actually lowered gene repair in HeLa cells
containing >50 copies of the target gene, our results are
consistent with other reports that a thymidine pre-treat-
ment is able to elevate gene repair several fold over basal
levels.
It is widely known that the addition of thymidine to a
mammalian cell culture leads to a synchronization of cells
in the G1 phase of the cell cycle or at the G1/S border
[29,30]. When cells are released from the thymidine
block, a large fraction of the population proceeds into S
phase, resulting in an increase of ideal cellular targets for
ssODN site association and thus, gene repair activity
appears maximized [19,26]. As shown in Figure 2A, the
addition of 1 mM thymidine restructures the cell cycle
profile such that the majority of cells are primarily stalled
in G1, minimally in S phase, and with only a small frac-
tion in G2 (Figure 2A: ii). By 8 hours after the release of
the thymidine block, the cells begin to transition into S
phase (Figure 2B: ii), while the non-treated samples
remain predominantly at the same cell cycle proportions
from the time of oligo addition to 8 hours following elec-
troporation (Figure 2A: i and Figure 2B: i). At 8 hours, a
majority of the cells released from the thymidine treat-
ment contain actively replicating chromosomes (Figure
2B: iii), as assayed by BrdU incorporation. Under these
conditions, the number of actively replicating cells is
A 24 hour pre-treatment with thymidine enhances gene repair levels Figure 1
A 24 hour pre-treatment with thymidine enhances gene repair levels. Various concentrations of thymidine were added to 
a growing culture of DLD-1 cells 24 hours prior to the introduction of 1 μM oligonucleotide (EGFP3S/47NT). Cells were 
allowed to recover for 48 hours after electroporation and were harvested for FACS analysis. Correction efficiency is reported 
as the percent of live green fluorescent cells in the total cell population (50,000 per experiment); mean and standard deviations 
were calculated based on values obtained from 3–4 samples per treatment. T-tests were performed comparing the 1 mM and 
8 mM thymidine pre-treatment to the 0 mM sample (***p < 5 × 10-5).BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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almost twice as high as the level seen in cells that have not
been pretreated with thymidine (Figure 2B: iv vs. 2Biii),
an observation that could reflect the increased number of
cells in S phase. Thus, the addition of thymidine and its
subsequent removal stimulates gene repair activity by ena-
bling more cells to be in S phase when the ssODN initial-
izes the gene repair reaction.
Thymidine is able to stimulate and maintain substantial 
levels of gene repair
After observing the increase in gene repair levels at 48
hours following a 24 hour thymidine pre-treatment, we
wanted to examine if this increase remains stable over
time, beyond the 48 hour incubation. For this study, we
repeated the experiment outlined in Figure 1 using a sin-
gle concentration of thymidine (1 mM) during the pre-
incubation phase and measured correction levels at 48
and 144 hours after ssODN electroporation. Although the
initial stimulation is seen at 48 hours post electropora-
tion, Figure 3 illustrates an important phenomenon in
which the absolute level of correction decreases with time,
corroborating the initial finding reported by Olsen et al.
[12,16]. As shown, a statistically significant decrease in
repair levels is seen between the 48 and 144 hour time
points (approximately 3-fold) for both the pretreated
(Figure 3: bar d vs. c) and untreated (Figure 3: bar b vs. a)
samples. It has been suggested previously by our group
that this lack of maintenance of the correction efficiency is
due to the induction of the DNA damage response path-
way and its subsequent activation of the checkpoint pro-
teins Chk1 and Chk2. Hence, a "dilution" of the corrected
cells is seen as the non-corrected cell population prolifer-
ates at normal rates while the corrected cells appear stalled
[22].
Based on this observation, we wanted to examine the idea
of controlling replication of the entire cell population as a
means of preventing the decrease of correction levels over
time. Our reasoning behind this was to transiently inhibit
the replication and division of non-corrected cells until
the corrected cells were able to resume normal replication.
Accordingly, we wanted to utilize thymidine and its abil-
ity to stall cell replication as a tool to slow down the entire
cell culture, in hopes of maintaining the high initial levels
of correction for extended periods of time. To address this
aim, we treated the cells with 1 mM thymidine for 24
hours prior to the introduction of the 47-mer EGFP3S/
47NT and then divided the samples into three distinct
groups. The first group of cells was grown in the absence
of thymidine for either 48 or 144 hours (Figure 4: a and b)
while the second group was grown for 48 or 144 hours in
the presence of 2 mM thymidine (Figure 4: c and d). The
last group was grown in thymidine for only 48 or 72 hours
after electroporation (Figure 4: e and f, respectively), at
which point the thymidine was washed out (indicated as
"w/o") and the incubation continued for a total of 144
hours in complete medium. The combination of a 1 mM
pre- and a 2 mM post-treatment was optimized to produce
first an initial increase in repair frequency followed by a
sustained level of this with minimal cytotoxicity, data not
shown. When no thymidine was present in the post-elec-
troporation cultures, the correction efficiency decreased
significantly between the 48 and 144 hour time points,
coinciding with the data in Figure 3. In contrast, when 2
mM thymidine was added to the cultures following elec-
troporation, the correction efficiency was largely main-
tained between 48 and 144 hours at levels significantly
above those for the non-treated samples at corresponding
time points. In a similar fashion, by removing thymidine
after only a 48 or 72 hour incubation, correction efficien-
cies still remained significantly higher at 144 hours than
with out any thymidine post-treatment. Taken together,
these data suggest that the presence of thymidine in the
post-electroporation reaction results in a maintained level
of gene repair for an extended period of time.
Thymidine addition induces cell senescence in DLD-1 cells 
under certain reaction conditions
After extended culturing in the presence of thymidine, we
noticed morphological changes within our cultures that
resembled a senescent phenotype, including flattened cell
morphology with elongated cellular processes and
enlarged nuclei [31]. To confirm these cellular changes,
cultures were stained for senescence associated β-galactos-
idase (SA β-gal) expression [32,33]. In Figure 5A, repre-
sentative fields of cells treated with thymidine under two
different conditions are shown at 48, 72 and 144 hours
after introduction of the ssODN. No evidence of senes-
cence is observed in the 48 or 72 hour cultures under
either condition (1-0 mM or 1–2 mM). However, cells
pretreated with 1 mM thymidine and incubated in 2 mM
thymidine after electroporation (1–2 mM) develop a
senescent phenotype within 144 hours, as evident by the
presence of blue stain in approximately 50% of these cells.
In Figure 5B (i, ii, and iii), multiple images obtained at the
144 hours under the 1–2 mM thymidine condition are
presented, further highlighting the positive SA β-gal
expression. The left-hand panels, showing cell morphol-
ogy, were photographed under phase contrast while the
panels on the right, aimed to enhance the blue color, were
photographed with bright field illumination. Here, the
evidence for certain reaction conditions inducing cellular
senescence is more compelling and this transition to a
senescent phenotype could further explain the mainte-
nance of gene correction over 144 hours with the 1–2 mM
thymidine treatment combination. In contrast, Figure 6
presents cells incubated for 144 hours with thymidine
having been washed out at 48 or 72 hours, post-electropo-
ration. Here, we observe a minimal number of senescent
cells at the 48 hour wash-out (less than 10% of the cells)BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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Pre-treatment with thymidine arrests cells in G1 and once removed, allows a synchronous entry into S phase Figure 2
Pre-treatment with thymidine arrests cells in G1 and once removed, allows a synchronous entry into S phase. (A) Thy-
midine was added at 1 mM (ii) or 0 mM (i) for 24 hours, cells were then harvested and processed for cell cycle analysis, repre-
senting the cell cycle profile at the time of oligonucleotide electroporation. (B) Cells were treated for 24 hours as in A, but 
were washed 2× with PBS at 24 hours and released into fresh media for 8 hours, at which time they were either collected for 
cell cycle analysis (i and ii) or were stained for BrdU incorporation (iii and iv) to measure their replicative state. The position of 
M1 (BrdU+ marker) was determined by a BrdU(-) control, not shown, and percents indicate the number of cells that are posi-
tive for BrdU in the total sample size (25,000 cells).BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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but a significant number is observed when the thymidine
is washed out at 72 hours (about 38% of the culture), sug-
gesting that the transition to wide-spread senescence most
likely occurs shortly after this point. Furthermore, it is
important to note that corrected cells are neither apop-
totic nor senescent (Ferrara et al., submitted), suggesting
that the transition to the apoptotic state is simply as a
result of the thymidine incubation. In addition, pro-
longed treatments with thymidine did not show evidence
of cell death, as determined by a MTT (3-(4,5-Dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide) cell viabil-
ity assay in which the level of production of the purple
formazan remained unchanged during the incubation
(data not shown).
Prolonged incubation with thymidine leads to a slow-down 
in DNA replication and cell division
As shown in Figure 2A, the exogenous addition of thymi-
dine to a DLD-1 cell culture results in an accumulation of
cells in G1 or at the G1/S border. In effect, thymidine
reduces the overall rate of DNA replication in a popula-
tion of cells by synchronizing them into G1 and prevent-
Over time, gene repair levels diminish regardless of thymidine pre-treatment Figure 3
Over time, gene repair levels diminish regardless of thymidine pre-treatment. Cells were treated either with no thymidine (a 
and b) or with 1 mM thymidine (c and d) for 24 hours prior to electroporation of the oligonucleotide. The cells were then allowed 
to recover for 48 hours (a and c) or 144 hours (b and d), at which points they were harvested and measured by FACS for eGFP 
expression. The correction efficiency reports the percent of the total number of cells (50,000 in each sample) that are live and 
positive for eGFP fluorescence. The mean and standard deviations were calculated based on the results from 4 individual samples 
of each treatment/time point; T-tests were performed comparing samples a to b and c to d (***p < 5 × 10-4).BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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ing their entry into S phase. Thus, the presence of
thymidine in a gene repair reaction could simply be main-
taining the relative percentages of corrected and non-cor-
rected cells between 48 and 144 hours by inhibiting the
replication of the entire cell population and there by, pre-
venting the dilution of the corrected cells. To examine this
possibility, we measured the capacity of cells to incorpo-
rate BrdU, which would indicate the percent of cells
undergoing active replication at 48, 72, and 144 hours.
When the population was pretreated with thymidine for
24 hours followed by a removal of the thymidine at the
time of electroporation (Figure 7: 1-0 mM), replication
activity remained fairly constant overtime. In contrast,
when the pretreatment was followed by sustained incuba-
tion in thymidine following electroporation (Figure 7: 1–
2 mM), replication activity dropped dramatically and lit-
tle incorporation of BrdU was evident. Thus, it seems
likely that the maintained correction efficiency seen
between 48 and 144 hours under the latter condition (1–
2 mM) is due to an overall inhibition of DNA replication
Combining the 1 mM thymidine pre-treatment with a 2 mM post-treatment retains high levels of gene repair Figure 4
Combining the 1 mM thymidine pre-treatment with a 2 mM post-treatment retains high levels of gene repair. Cells 
were treated with 1 mM thymidine for 24 hours, electroporated with 1 μM EGFP3S/47NT oligo, and recovered in complete 
medium without thymidine (a and b) or in the presence of 2 mM thymidine (c through f) for 48 hours (a and c) or for 144 
hours (b and d-f). At 48 and 72 hours, sample e and f, respectively, were washed 2× with PBS and fresh medium was added that 
did not contain any thymidine (termed "w/o" for "washed out"); these cells were collected at 144 hours and analyzed by FACS 
for eGFP fluorescence. Correction efficiency depicts the percentage of live green fluorescent cells in the total number of cells 
counted (50,000 per sample); means and standard deviations were calculated based on the results of three to four independent 
experiments. T-tests were performed comparing b to d and e (**p < 0.05).BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
Page 8 of 16
(page number not for citation purposes)
Prolonged exposure to thymidine results in cellular senescence Figure 5
Prolonged exposure to thymidine results in cellular senescence. (A) Following a 1 mM thymidine 24 hour pre-treatment, 
cells were electroporated and released into complete medium (1-0 mM) or medium supplemented with 2 mM thymidine (1–2 
mM). At 48, 72 and 144 hours, cells were stained for the senescent marker β-galactosidase. The four quadrants for the 1–2 
mM sample at 48 hours are combined images obtained from four different fields of view, due to the low confluency of the sam-
ple. (B) Images depict varying views and different wells of the 1–2 mM thymidine treated cells at 144 hours. All images are at 
20× magnification and counts of individual cells in a representative field were performed to evaluate the degree of senescence 
induction.BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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and in part by the entry into cellular senescence, as seen in
Figure 6. However, when thymidine was washed out at 48
or 72 hours (Figure 7: 1–2 mM w/o 48 hrs and 1–2 mM
w/o 72 hrs, respectively), and cells allowed to resume
growth in complete medium, DNA replication resumed,
reaching approximately half the normal level of activity
by 144 hours of incubation. More importantly, this wash-
out protocol preserved high levels of correction efficiency
between 48 and 144 hours (see Figure 4). Therefore, the
presence of thymidine during the early times of the gene
repair reaction appears to help maintain correction levels
without irreversibly disabling the capacity of the cell to
resume DNA replication.
In order to confirm these results and to evaluate the
potential residual effects if thymidine on the cell cycle fol-
lowing the wash-out protocol, we utilized an assay to
determine division rates of cells. PKH26, a fluorescent cell
label that binds irreversibly within the lipid region of cell
membranes, was used to determine rate and extent of cell
proliferation following the removal of the thymidine post
electroporation. As cells divide following intercalation of
the dye, each resulting daughter cell receives half of the
fluorescent dye during subsequent rounds of cell division
[34,35]. Thus, by using flow cytometric analysis to meas-
ure the change in fluorescence intensity of PKH26, we are
able to estimate the number of divisions a cell population
has undergone within a given period. At time zero (T0), or
at the time of electroporation following a 1 mM thymi-
dine pre-treatment, cells were labeled with PKH26 and the
starting mean fluorescence intensity (m.f.i.) was found to
be 254.8 (Figure 8: i). At 48 hours following staining, cells
that received no thymidine in the post treatment (Figure
8, ii) displayed a shift in their mean fluorescence intensity
to 62.6, corresponding to two cellular divisions, and again
at the 144 hour point (Figure 8: iii), indicating an addi-
Removal of the 2 mM thymidine post-treatment at 48 hours, but not at 72 hours, prevents cellular senescence Figure 6
Removal of the 2 mM thymidine post-treatment at 48 hours, but not at 72 hours, prevents cellular senescence. Cells 
were treated with 1 mM thymidine prior to electroporation and then recovered in 1 mM thymidine. At 48 hours and 72 hours, 
as indicated, cultures were washed 2× with PBS and fresh medium was added ("w/o": washed out). At 144 hours, cells were 
assayed for senescence-associated β-galactosidase activity. All images are at 20× magnification.BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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Cells are able to resume replication after the removal of 2 mM thymidine during recovery Figure 7
Cells are able to resume replication after the removal of 2 mM thymidine during recovery. Cells were treated with 1 
mM thymidine for 24 hours, electroporated, and recovered in 2 mM thymidine (1–2 mM) or without thymidine (1-0 mM). At 
48, 72, and 144 hours, the culture media was supplemented with BrdU and cells were later assayed by FACS for its incorpora-
tion. The 1-0 mM culture reached confluency by 96 hours and was passaged once prior to the 144 hour time point. The w/o 
("wash out") samples received 2 mM thymidine in the recovery phase, which was subsequently washed out at 48 and 72 hours, 
respectively, and later assayed at 144 hours for BrdU incorporation. Position of M1 (BrdU+ marker) was determined by a 
BrdU(-) control, not shown, and percents indicate the number of cells that are positive for BrdU incorporation out of the total 
population (25,000 cells).BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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tional three cell divisions (total of 5 within the 144
hours). In contrast, with thymidine in the post treatment
for 48 hours (Figure 8: iv), there was an insignificant
change in the mean fluorescent intensity, indicating that
no cell division had occurred. Following the removal of
thymidine at 48 hours, the cells underwent 2.5 cell divi-
sions by 144 hours (Figure 8: v), as determined by the
change in the mean fluorescence intensity from 48 hours.
Thus, it seems as if washing out thymidine at 48 hours can
enable cell division to resume at a rate nearly that of the
1-0 mM counterpart. Combined with the BrdU data, a
case can be made that the maintenance of correction effi-
ciency is accompanied by DNA replication and normal
cell division processes following the removal of thymi-
dine.
Discussion
Drury and Kmiec [36] demonstrated the importance of
target association in the gene repair reaction and sug-
gested that the rate-limiting step is the pairing of the
ssODN to the genomic site. Thus, we assume that strate-
gies aimed at increasing correction levels might be facili-
tated by events that enable more efficient oligonucleotide
binding. Several agents have been employed to achieve
this goal including trichostatin A (TSA), which is a potent
histone deacetylase inhibitor [37]. When added to cell
cultures following ssODN delivery, TSA was able to
increase gene repair up to 10-fold, most likely by altering
the chromosome structure and enabling oligonucleotide
binding [38]. Slowing down the process of DNA replica-
tion by extending S phase or synchronizing cells in S is
another way to enhance the frequency of gene repair
[14,18,19,39].
Following the removal of 2 mM thymidine from the post-treatment, cells are able to resume cell division at rates comparable  to no treatment samples Figure 8
Following the removal of 2 mM thymidine from the post-treatment, cells are able to resume cell division at rates com-
parable to no treatment samples. Following a 24 hour 1 mM pre-treatment with thymidine, cells were collected and stained 
with the cell-membrane dye, PKH26, and then released into medium supplemented with 2 mM thymidine (iv and v) or com-
plete medium (ii and iii). Fluorescence of the PKH26 dye was measured in a subset of the cells immediately following staining 
and prior to re-plating to obtain an initial fluorescence value (i: T0); subsequent samples were removed at 48 (ii and iv) and 144 
hours (iii and v) following re-plating for the same analysis. Sample (v) was washed 2× with PBS at 48 hours, received fresh 
medium and analyzed at 144 hours. Values indicate the mean fluorescence intensity (m.f.i.) of the population at each time point 
(shaded peak); non-shaded graph represents the fluorescence levels at T0 and filled in graphs represent the fluorescence inten-
sity at the indicated times. M1 is the boundary for the PKH26(-) samples and M2 indicates PKH26(+) fluorescence.BMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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Our current work focused on examining this second
manipulation in greater detail by studying more carefully
the function of S phase in gene repair. During this phase
of the cell cycle, chromatin is in a more open conforma-
tion, accessible to proteins/DNA complexes that undergo
a search for homology and interact at specific sites within
the genome. In this study, we confirm that incubating
cells with thymidine leads to elevated gene repair levels by
synchronizing the cells along the G1/S border and
enhancing the total number of amenable targets when,
after release, the cells cycle into S phase in the presence of
the oligonucleotide [10,22]. We also show that the inher-
ent loss of gene correction with time [12] can be counter-
balanced by inhibiting the replication of the entire cell
population, and preventing the "dilution" of the repaired
population of cells by the unimpeded non-corrected cell
population. Lastly, we present a novel finding that shows
that the long term effect of thymidine treatment can result
in the induction of cellular senescence.
Treatment with thymidine leads to an increased level of
cellular dTTP, ultimately resulting in a feedback inhibi-
tion of ribonucleotide reductase. Subsequently, cells are
starved of dCTP, due to the allosteric inhibition of the
reduction of CDP [40], resulting in a slowing of DNA rep-
lication and an accumulation of cells that traverse S phase
(referred to as a thymidine block [24]. By incubating
DLD-1 cells in 1 mM thymidine for 24 hours, we were
able to stall approximately 90% of the cell population at
the G1/S border. Following the introduction of the oligo-
nucleotide, the block was removed and the cells were
allowed to enter S and G2 in the presence of the ssODN.
The high repair efficiency seen with thymidine pre-treat-
ment was most likely due to the increased number of
accessible target sites that in S (3 times more cells than in
the non-synchronized cells) or cycling through S within
the first 8 hours following electroporation. Upon removal
of thymidine, cells were able to once again replicate at
high levels further indicating the increased number of
cells in S phase. Thus, our data indicate that elevated levels
of correction are mostly due to an increase of cellular tar-
gets in S phase, whose open chromatin structures facilitate
ssODN association and ultimately gene repair events.
These results on the importance of S phase in the ssODN-
coupled repair differs from the conclusions drawn in Wu
et al. [14] that increasing the proportion of cells in S phase
does not enhance repair levels. Our data contrast these
observations by identifying S phase as the critical cell cycle
stage in which gene repair occurs. We find that the highest
overall gene repair was evident at 8 hours following the
ssODN introduction, for both 1 mM thymidine pre-
treated and non-treated cells (0.66% and 0.12%, respec-
tively; see Additional file 1). In addition, the maximal
value occurred following the 1 mM thymidine pre-treat-
ment, coinciding with the highest percent of cells in S
phase at 8 hours. When cells were pre-treated with thymi-
dine and then sustained in thymidine for 8 hrs following
ssODN electroporation, gene repair decreased to only
0.21% by this time point, concurrent with an altered cell
cycle profile in which a lower percent of cells were in S
phase and a higher percent remained at G1 or in early S
(see Additional file 2). However, when thymidine was
simply added after ssODN introduction (without a pre-
treatment), gene repair levels and cell cycle profiles
remained remarkably unchanged, as compared to the
non-treated non-synchronized cells. Thus, our results sup-
port the aforementioned observation that highlights the
importance of S phase in the gene repair reaction. What is
interesting to note, however, is the fact that although the
gene repair is lower when thymidine is used in both the
pre- and post-treatment, its repair level remains constant
from 8 to 48 hours while a decrease is observed when thy-
midine is removed following the addition of the ssODN.
Ultimately, this change in repair frequency results in the
appearance of higher levels of gene repair following a 1–2
mM thymidine treatment than a 1-0 mM at 48 hours fol-
lowing ssODN introduction (see Figure 4, bar a and c).
Recently, it was reported that the repair frequency
decreases as a function of recovery time following ssODN
introduction, and this lack of maintenance of the repair
frequency is due to the selective recovery and proliferation
of non-corrected cells [12,22]. Although it is unclear
whether the corrected cells are arrested in late S phase [22]
or at the G2/M border [12], it is apparent that the single-
stranded DNA oligonucleotide activates a damage
response pathway through the upregulation and auto-
phosphorylation of ATM [11,22,41]. This activation, in
turn, leads to a phosphorylation of the downstream
checkpoint kinases, Chk1 and Chk2 at Ser317 and/or Ser
345 and at Thr68, respectively [22,42-45]. Due to the
induction of the damage response and the specificity of
the Chk1 and Chk2 activation within the corrected cells,
these cells are preferentially stalled in the cell cycle and do
not divide. In contrast, the non-corrected cells do not uni-
formly contain activated Chk1/Chk2 and thus, no halt of
cellular replication is observed [22]. Because of this linger-
ing cell cycle block, the overall correction frequency
appears to decrease as the non-corrected cells resume nor-
mal replication while the vast majority of corrected cells
become arrested. In contrast to our system in which cor-
rection efficiency is measured among a background of
non-corrected cells, protocols that utilize selection to iso-
late corrected cells, in effect, exclude all other cells from
the population, only allowing corrected non-arrested cells
to continue to grow. Because of this, non-corrected cells
are not able to out compete and over grow the corrected
cells, and thus, a decrease in gene repair is not evident
[46]. In a more biologically relevant target, in which thereBMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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is no such selective pressure, however, it is imperative to
accommodate and respond to the varying replicative abil-
ities of both the non-corrected and corrected cell popula-
tions.
In this report, we establish a protocol that utilizes a thymi-
dine treatment following the introduction of the oligonu-
cleotide, allowing for a population wide reduction in
DNA replication activity, regardless of correction state of
the individual cells. The post-treatment led to a decrease
in cell replication by an average of nearly 8 fold at each
time point and as a result, correction levels remained con-
stant. This observation was also true for cells not pre-
treated with 1 mM thymidine prior to oligonucleotide
electroporation (data not shown). In addition, removing
the thymidine following ssODN electroporation at 48
hours and 72 hours allowed for the maintenance of sub-
stantial levels of correction up to 144 hours. The wash-out
of the thymidine treatment was accompanied by the
resumption of cellular replication and a normal division
rate. This implies that thymidine can be used to slow the
replication of the entire cell culture temporarily in order
to preserve a high level of gene correction.
In contrast, treating the cells with 2 mM thymidine for
144 hours resulted in the population entering into cellu-
lar senescence, as determined by a physiological change in
cell morphology and a positive staining for SA β-galactos-
idase. Interestingly, the development of senescence was
time-dependent as removal of thymidine at 48 hours, but
not 72 hours, in an assay lasting 144 hours showed a min-
imal number of senescent cells, indicating that there is a
window of time in which the transition between survival
and senescence is determined.
Normal cells can revert to a state of replicative senescence
within several days, when exposed to certain physiologi-
cal stress factors [see [47,48] and references therein]. In
addition, hydroxyurea (HU), which depletes cells of
dNTPs and rapidly shuts down cell replication [49,50],
has been shown to induce senescence following a long
treatment [51,52]. Not only could the entry into senes-
cence after a prolonged treatment with thymidine be due
to the cellular stress following an imbalance of ribonucle-
otide reductase, but also due to activation of other path-
ways that lead to cell senescence. Excess thymidine in the
cell has been shown to activate an ATM-mediated protein
kinase cascade which is followed by an ATR-mediated
response; both of which are required for cell survival fol-
lowing the treatment [53]. The response is believed to
emanate from an alteration in the chromatin state [54] or
the formation of an altered DNA structure, known as a
"chicken foot," following genome-wide stalling of replica-
tion forks [53,55-57], which p53 is able to recognize and
bind to [58]. Both structures can activate ATM and along
with a prolonged p53 induction, has been shown to medi-
ate the onset of a senescent phenotype [59-61].
Conclusion
Thus, based on these data, it is clear that the maintenance
of gene conversion levels resulting in a 144 hour thymi-
dine treatment may be due to the overall stalling in cell
replication and an eventual entry into the senescent state.
On the contrary, the wash out protocol at 48 hours was
able to prevent this senescence transition followed by a
reversal of the cell replication and division effects, and
thus, may be a useful tool to increase and sustain high lev-
els of gene repair.
Methods
Cell line and culture conditions
DLD-1 cells were purchased from American Type Cell Cul-
ture (ATCC, Manassas, VA). The integrated DLD-1 clone
one (DLD-1-1) was obtained by integrating the pEGFP-
N3 vector containing a single point mutation (TAG) in the
chromophore region of the eGFP gene, and "clone one,"
containing 2–3 copies of the mutated eGFP, was isolated
through serial dilution [see [18]]. For these experiments,
cells were grown in RPMI 1640 medium supplemented
with 2 mM glutamine, 4.5 g/l glucose, 10 mM HEPES, 1
mM sodium pyruvate, and supplemented with 10% FBS.
Cells were maintained at 37°C and 5% CO2 and kept
under selection by the addition of 200 μg/ml G418 to the
media (Gibco, Invitrogen Co., Carlsband, CA).
Oligonucleotide Designs, eGFP targeting, and flow 
cytometry analysis
EGFP3S/47NT (IDT, Coralville, IA) is single stranded
DNA oligonucleotides 47 nucleotides long containing
three phosphorothioate linkages at both the 5' and 3'
ends. This oligonucleotide was designed to be compli-
mentary to the non-transcribed strand and contains a mis-
match at the site of the desired base change, which
converts the mutant stop codon to the wild type TAC
(encoding tyrosine), restoring the expression of eGFP in
corrected cells. Previous publications have shown that
neither a non-specific nor a perfectly matched oligonucle-
otide is able to foster this conversion [18].
For the eGFP targeting experiments, DLD-1 cells were sub-
cultured at a density of 1.6 × 106 cells per 100 mm dish 24
hours prior to targeting. Following this incubation, cells
were washed with PBS, trypsinized, centrifuged, and re-
suspended in serum-free medium at a concentration of 2
× 106 cells/100 μl; 100 μl was transferred to a 4 mm gap
cuvette (Fisher Scientific, Pittsburgh, PA). The EGFP3S/
47NT oligonucleotide was added at a concentration of 1
μM and the cells were electroporated (LV, 250 V, 13 ms, 2
pulses, 1 s interval) using a BTX Electro Square Porator™
ECM830 apparatus (BTX, Holliston, MA). The cells wereBMC Molecular Biology 2007, 8:9 http://www.biomedcentral.com/1471-2199/8/9
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then transferred to a 60 mm dish (100 mm for incuba-
tions exceeding 48 hours) containing fresh medium sup-
plemented with 10% FBS and incubated for the indicated
time points at 37°C before harvesting for FACS or other
analysis, as indicated.
eGFP fluorescence of corrected cells was measured by a
Becton Dickinson FACS calibur flow cytometer (Becton
Dickinson, Rutherford, NJ.). For eGFP fluorescence, cells
were harvested after electroporation (between 8 and 144
hours, as indicated) and re-suspended in FACS buffer
(.5% BSA, 2 mM EDTA, 2 μg/ml propidium iodide in
PBS). 50,000 cells were analyzed for each sample and the
cells that were eGFP positive (corrected) and PI negative
(live) were scored as "corrected." Settings for the FACS cal-
ibur were determined as previously described [21].
Thymidine treatment
Thymidine was obtained from Sigma-Aldrich (St. Louis,
MO.) with a stock solution prepared in distilled water to
a final concentration of 500 mM and added to incubating
cells at a final concentration of 1–12 mM, as indicated.
The term "pre-treatment" indicates addition of thymidine
at the start of the 24 hour incubation prior to electropora-
tion; "post-treatment" refers to the addition of thymidine
to the 60 mm or 100 mm dishes following electropora-
tion, in the recovery phase. Washing out of thymidine
refers to the removal of the agent from the cell culture by
aspirating off medium, washing the cells twice with PBS,
and adding fresh medium containing FBS. For incuba-
tions exceeding 72 hours in the presence of thymidine,
cells were washed twice with PBS and fresh medium was
added in addition to thymidine at the 72 hour mark, to
maintain desired thymidine concentration.
BrdU cell replication assay, PKH26 cell division, and cell 
cycle analysis
BrdU, 5-Bromo-deoxyuridine, was obtained from Roche
Applied Science (Indianapolis, IN). Cells were treated as
for gene targeting and the time points indicated, 10 μM
BrdU was added to the growth medium. Cells were incu-
bated for 30 minutes at 37°C and then washed three
times with PBS and DNA was denatured in 0.2 M HCl for
1 h at 37°C. After two washes in 0.1 M sodium borate and
three washes in PBS, cells were blocked in PBS-0.5%BSA-
0.1% Tween-20 for 20 min. Cells were then incubated for
1 hour at room temperature with Anti-BrdU-fluorescein
antibody (Roche Diagnostics, Switzerland) diluted in
PBS-0.1% BSA at a final concentration of 25 μg/ml.
PKH26 (MINI-26 Red Fluorescent Cell Linker Mini Kit)
was obtained from Sigma-Aldrich (St. Louis, MO.) and
the supplied protocol was optimized for the DLD-1 cells.
About 5 × 106 cells were collected and washed once with
PBS, cells were resuspended in 200 μl Diluent C, equivol-
ume of PKH26 at 8 × 10-6 M in Diluent C was added, and
incubated at room temperature for 5 minutes, with occa-
sional agitation. 400 μl 1% BSA was added for 1 minute at
room temperature to stop the reaction. 800 μl DLD-1
medium containing FBS was added, cells were spun down
at 1500 rpm for 5 minutes, medium was aspirated off and
cells were re-suspended in 800 μl PBS and transferred to a
clean tube. Cells were washed twice more with PBS and re-
suspended in DLD-1 medium prior to plating. An aliquot
was removed to determine mean fluorescence intensity
(m.f.i.) immediately following staining (T0), the remain-
ing cells were plated in the conditions noted and their flu-
orescence was measured at 48 or 144 hours (T48 and
T144, respectively), as indicated. Detection of PKH26 was
done via flow cytometry, using a rhodamine filter.
For cell cycle analysis, cells were treated as indicated, har-
vested and washed in PBS. They were then spun at 1200
rpm for 5 minutes, re-suspended in 500 μl cold PBS and
fixed by adding 5 ml of 70% cold ethanol while vortexing.
Following a 4°C incubation, the cells were centrifuged for
5 minutes at 2000 rpm, washed once with PBS and then
re-suspended in 300 μl FACS buffer (50 μg/ml RNase A,
2.5 μg/ml PI, 1% FBS in PBS). The cells were incubated at
37°C for 1 hour and at 4°C over night before analysis by
flow cytometry. DNA content was analyzed and data were
plotted as DNA content versus cell number; cell cycle
modeling was performed and the percent of cells in G0–
G1, S, and G2-M phase was calculated using Modfit (Verity
Software House, Topsham, ME.).
Senescence associated β-Gal assay
At the indicated times, cells were washed twice with PBS
and fixed with 4% paraformaldehyde for 10 minutes at
room temperature. β-gal staining solution (40 mM citric
acid/sodium phosphate, pH 6.0; 150 mM NaCl; 2 mM
MgCl2; 5 mM potassium ferrocyonide; 5 mM potassium
ferricyonide; 1 mg/ml X-gal) was added and plates were
incubated over night at 37°C. Following this, cells were
washed twice with PBS and re-suspended in PBS for
microscopy studies. Cells were viewed under phase con-
trast and to enhance the blue staining, a bright field illu-
mination was used. Images were obtained by a Nikon
Coolpix 995 digital camera at 20× magnification.
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Additional File 1
Gene repair at 8 hours following ssODN electroporation. Cells 
were treated either with or without 1 mM thymidine for 24 hours prior to 
the electroporation of 1 μM EGFP3S/47NT and a subset of the samples 
was allowed to recover in the presence of 2 mM thymidine. Gene repair 
was assayed by flow cytometry at 8 hours following the introduction of the 
ssODN and correction is given as the percent of GFP(+)/PI(-) [fluoresc-
ing, live] cells out of the 50,000 cells analyzed. The data shows that the 
pre-treatment with 1 mM thymidine resulted in a greater than a 5 fold 
increase in gene repair (0.12% vs. 0.66%), as compared to the non-
treated sample. The addition of 2 mM thymidine in the recovery led to a 
3 fold decrease in repair frequency of the pre-treated sample (0.21% vs. 
0.66%) but did not alter the correction levels of the no pre-treated sample 
(0.11% vs. 0.12%).
Click here for file
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Additional File 2
Cell cycle profile at 8 hours in the presence of a 2 mM thymidine 
post-treatment. Cells were cultured for 24 hours in the presence or 
absence of a 1 mM thymidine pre-treatment, electroporated with 1 μM of 
the oligonucleotide and then recovered in 2 mM thymidine. After an 8 
hour recovery period, the cells were trypsinized and fixed to be processed 
for cell cycle analysis, as outlined in the methods section. When cells were 
not pre-treated with thymidine, the post-treatment did not alter the cell 
cycle profile (G1: 59%; S: 27%; G2/M: 14%). However, when the post-
treatment followed the 1 mM thymidine pre-treatment, a considerable 
percent of cells remained in G1 or early S (G1: 62%; S: 36%; G2: 2%).
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